Biotherapy Treatment: Mesothelin-Targeted Therapies

  • Lisa BengtsonEmail author


The use of targeted therapies can provide mesothelioma patients with innovative treatment options. Mesothelin is a protein expressed in mesothelioma as well as other cancers including pancreas, ovarian, and lung cancer. A number of agents have been evaluated as potential treatments for malignant mesothelioma, including immunotoxins, monoclonal antibodies, antibody drug conjugates, vaccines, and chimeric antigen receptor T cells (CAR-T cells). Each targeted therapy has a unique toxicity profile, which requires a team of specialists to appropriately treat and resolve those toxicities. This chapter focuses on the role of mesothelin as a biological target of treatment.


  1. Hassan R, Thomas A, Alewine C, Le DT, Jaffee E, Pastan I. Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol. 2016;34(34):4171–9.CrossRefGoogle Scholar
  2. Pastan I, Hassan H. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014;74:2907–12.CrossRefGoogle Scholar
  3. Zhao X, Subramanyam B, Sarapa N, Golflier S, Dinter H. Novel antibody therapeutics targeting mesothelin in solid tumors. Clin Cancer Drugs. 2016;3(2):76–86.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations